Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rIL-21 + Caelyx in Advanced Ovarian Cancer
NCT00523380Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2007
- Primary completion
- Jan 2009
- Modality
- Cytokines & Interferons
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of recombinant human interleukin 21 in ovarian cancer, sponsored by Novo Nordisk. Primary endpoint: Overall Response Rate at 6 months. Started Oct 2007; status: completed.
02
Drugs
recombinant human interleukin 21
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00523380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00523380.